K858 (Racemic)

K858 Racemic is an ATP-uncompetitive inhibitor of kinesin Eg5 with an IC50 of 1.3 μM.

Product Specifications

CAS Number

[72926-24-0]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Kinesin

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/K858.html

Purity

99.93

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(NC1=NN(C(C)=O)C(C2=CC=CC=C2)(C)S1)=O

Molecular Formula

C13H15N3O2S

Molecular Weight

277.35

Precautions

H302, H315, H319, H335

References & Citations

[1]Nakai R, et al. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. Cancer Res. 2009 May 1;69 (9) :3901-9.|[2]De Iuliis F, et al. The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells. Invest New Drugs. 2016 Aug;34 (4) :399-406.